HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the
"Company"), a clinical-stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of
Texas System on behalf of the MD Anderson Cancer Center,
today announced that Walter Klemp,
Chairman and CEO and Jonathan
Foster, Chief Financial Officer, will present at the
following investor conferences:
- Oppenheimer 29th Annual Healthcare Conference –
Management will present on Wednesday, March
20, 2019 at 3:20 p.m. ET. The
Conference will be held at the Westin New York Grand Central Hotel
in New York City.
- 31st Annual ROTH Conference – Management will be
available on Monday, March 18, 2019
for one-on-one meetings with investors. The Conference will be held
at the Ritz-Carlton Hotel in Dana Point,
CA.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical
company focused on the treatment of highly resistant cancers.
Moleculin has three core technologies, all of which are based on
discoveries made at M.D. Anderson Cancer Center by Dr. Waldemar Priebe and his team. The Company's
clinical-stage drugs are Annamycin, a Next Generation Anthracycline
being studied for the treatment of relapsed or refractory acute
myeloid leukemia, or AML, and WP1066, an Immune/Transcription
Modulator targeting brain tumors, pancreatic cancer and AML. The
Company is also engaged in preclinical development of additional
drug candidates, including additional Immune/Transcription
Modulators, as well as Metabolism/Glycosylation Inhibitors.
Moleculin's Next Generation Anthracycline, Annamycin, we believe,
is unlike any currently approved anthracyclines, as it is designed
to avoid multidrug resistance mechanisms with little to no
cardiotoxicity. Annamycin has preliminary clinical data suggesting
its potential to become the first successful therapy suitable for
the majority of relapsed or refractory AML patients and is
currently in two Phase I/II clinical trials. WP1066 is one of
several Immune/Transcription Modulators capable of stimulating
immune response to tumors by inhibiting the errant activity of
Regulatory T-Cells (TRegs) while also inhibiting key oncogenic
transcription factors, including p-STAT3, c-Myc and HIF-1α. These
transcription factors are widely sought targets that may also play
a role in the inability of immune checkpoint inhibitors to affect
more resistant tumors. Moleculin is also developing new prodrugs to
exploit the potential uses of inhibitors of glycolysis. The
Company's lead Metabolism/Glycosylation Inhibitor compound, WP1122,
provides an opportunity to cut off the fuel supply of tumors by
taking advantage of their overdependence on glucose as compared
with healthy cells. New research also points to the potential for
the glucose decoy (2-DG) within WP1122 to be capable of enhancing
the usefulness of checkpoint inhibitors.
For more information about the Company, please visit
http://www.moleculin.com.
Contacts
Joe Dorame,
Robert Blum or Joe Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-biotech-inc-to-present-at-the-oppenheimer-29th-annual-healthcare-conference-and-the-31st-annual-roth-conference-300813685.html
SOURCE Moleculin Biotech, Inc.